LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 125

Search options

  1. Article: Steatotic Liver Disease and Sepsis Outcomes-A Prospective Cohort Study (SepsisFAT).

    Krznaric, Juraj / Papic, Neven / Vrsaljko, Nina / Gjurasin, Branimir / Kutlesa, Marko / Vince, Adriana

    Journal of clinical medicine

    2024  Volume 13, Issue 3

    Abstract: ... ...

    Abstract Background
    Language English
    Publishing date 2024-01-30
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm13030798
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: The Role of Non-Alcoholic Fatty Liver Disease in Infections.

    Krznarić, Juraj / Vince, Adriana

    Life (Basel, Switzerland)

    2022  Volume 12, Issue 12

    Abstract: Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease, affecting one third of the Western population. The hallmark of the disease is excessive storage of fat in the liver. Most commonly, it is caused by metabolic syndrome ( ...

    Abstract Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease, affecting one third of the Western population. The hallmark of the disease is excessive storage of fat in the liver. Most commonly, it is caused by metabolic syndrome (or one of its components). Even though the development of NAFLD has multiple effects on the human organism resulting in systemic chronic low-grade inflammation, this review is focused on NAFLD as a risk factor for the onset, progression, and outcomes of infectious diseases. The correlation between NAFLD and infections is still unclear. Multiple factors (obesity, chronic inflammation, altered immune system function, insulin resistance, altered intestinal microbiota, etc.) have been proposed to play a role in the development and progression of infections in people with NAFLD, although the exact mechanism and the interplay of mentioned factors is still mostly hypothesized. In this article we review only the selection of well-researched topics on NAFLD and infectious diseases (bacterial pneumonia, COVID,
    Language English
    Publishing date 2022-12-07
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2662250-6
    ISSN 2075-1729
    ISSN 2075-1729
    DOI 10.3390/life12122052
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Case Report: Amphotericin B and Mefloquine as a Salvage Treatment of Alveolar Echinococcosis.

    Jelicic, Karlo / Papic, Neven / Viskovic, Klaudija / Vince, Adriana

    The American journal of tropical medicine and hygiene

    2023  Volume 108, Issue 3, Page(s) 581–583

    Abstract: Alveolar echinococcosis is an emerging zoonotic disease caused by the parasite Echinococcus multilocularis. Most patients are diagnosed at a late stage, when lifelong treatment with benzimidazoles is required to stop disease progression. However, for ... ...

    Abstract Alveolar echinococcosis is an emerging zoonotic disease caused by the parasite Echinococcus multilocularis. Most patients are diagnosed at a late stage, when lifelong treatment with benzimidazoles is required to stop disease progression. However, for patients who do not tolerate benzimidazole therapy, there are no alternatives. Here, we present a patient with advanced alveolar echinococcosis who was successfully treated with amphotericin B deoxycholate and mefloquine as a rescue therapy after he developed albendazole intolerance.
    MeSH term(s) Male ; Animals ; Humans ; Mefloquine/therapeutic use ; Amphotericin B/therapeutic use ; Salvage Therapy ; Echinococcosis/drug therapy ; Albendazole/therapeutic use ; Echinococcus multilocularis ; Anthelmintics/therapeutic use
    Chemical Substances Mefloquine (TML814419R) ; Amphotericin B (7XU7A7DROE) ; Albendazole (F4216019LN) ; Anthelmintics
    Language English
    Publishing date 2023-01-30
    Publishing country United States
    Document type Case Reports
    ZDB-ID 2942-7
    ISSN 1476-1645 ; 0002-9637
    ISSN (online) 1476-1645
    ISSN 0002-9637
    DOI 10.4269/ajtmh.22-0465
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: TGF Beta as a Prognostic Biomarker of COVID-19 Severity in Patients with NAFLD-A Prospective Case-Control Study.

    Susak, Frano / Vrsaljko, Nina / Vince, Adriana / Papic, Neven

    Microorganisms

    2023  Volume 11, Issue 6

    Abstract: Non-alcoholic fatty liver disease (NAFLD), the leading cause of chronic liver disease in Western countries, has been identified as a possible risk factor for COVID-19 severity. However, the immunological mechanisms by which NAFLD exacerbates COVID-19 ... ...

    Abstract Non-alcoholic fatty liver disease (NAFLD), the leading cause of chronic liver disease in Western countries, has been identified as a possible risk factor for COVID-19 severity. However, the immunological mechanisms by which NAFLD exacerbates COVID-19 remain unknown. Transforming growth factor-beta 1 (TGF-β1) has an important immunomodulatory and pro-fibrotic role, which has already been described in NAFLD. However, the role of TGF-β1 in COVID-19 remains unclear, and could also be the pathophysiology link between these two conditions. The aim of this case-control study was to analyze the expression of TGF-β1 in COVID-19 patients depending on the presence of NAFLD and COVID-19 severity. Serum TGF-β1 concentrations were measured in 60 hospitalized COVID-19 patients (30 with NAFLD). NAFLD was associated with higher serum TGF-β1 concentrations that increased with disease severity. Admission TGF-β1 concentrations showed good discriminative accuracy in predicting the development of critical disease and COVID-19 complications (need for advanced respiratory support, ICU admission, time to recovery, development of nosocomial infections and mortality). In conclusion, TGF-β1 could be an efficient biomarker for predicting COVID-19 severity and adverse outcomes in patients with NAFLD.
    Language English
    Publishing date 2023-06-13
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2720891-6
    ISSN 2076-2607
    ISSN 2076-2607
    DOI 10.3390/microorganisms11061571
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: COVID-19, pet mjeseci kasnije ; COVID-19, five months later

    Vince, Adriana

    Liječnički vjesnik

    2020  

    Abstract: Novi koronavirus, službeno nazvan SARS-CoV-2, koji uzrokuje novu infektivnu bolest COVID-19 (Coronavirus infectious disease 2019), pokorio je od prosinca 2019. do svibnja 2020. cijeli svijet uzrokujući pandemiju u kojoj je do sredine svibnja 2020. ... ...

    Abstract Novi koronavirus, službeno nazvan SARS-CoV-2, koji uzrokuje novu infektivnu bolest COVID-19 (Coronavirus infectious disease 2019), pokorio je od prosinca 2019. do svibnja 2020. cijeli svijet uzrokujući pandemiju u kojoj je do sredine svibnja 2020. oboljelo više od 4,7 milijuna ljudi, a umrlo 316.000.1 Pandemija je nakon Kine snažno zahvatila Europu, a nakon toga Ameriku koja ima kontinuirani porast broja slučajeva od početka travnja s dnevnim prirastom od 25.000 novooboljelih tijekom svibnja, što čini Sjedinjene Američke Države najpogođenijom zemljom koja do sada bilježi 30% svih potvrđenih slučajeva COVID-a. Nezaposlenost u svijetu raste, a Međunarodni monetarni fond proglasio je ovu krizu najvećom od vremena depresije u tridesetim godinama 20. stoljeća. Ovakva situacija prisilila je brojne zemlje da zatvore granice i primijene različito stroge epidemiološke preventivne mjere. Većina zemalja primijenila je kroz nekoliko tjedana potpuno „zatvaranje” uz zabranu kretanja, okupljanja, rad od kuće, zatvaranje vrtića, škola, fakulteta, javnih prostora, parkova, uslužnih djelatnosti, gradskog i međugradskog prometa. Međunarodni zračni promet je minimaliziran, milijuni ljudi ostali su bez posla, svjetska ekonomija je naglo usporena s nejasnom perspektivom oporavka. Ipak, mnogo je još nepoznanica o virusu za koji znanstvenici smatraju da se prvi put pojavio među ljudima u studenom 2019. godine. U preglednom članku istaknute su dosadašnje spoznaje o epidemiološkim, patogenetskim i kliničkim značajkama virusa i bolesti koju uzrokuje, s osvrtom na liječenje, cjepivo i perspektivu pandemije.

    A new coronavirus, officially named SARS-CoV-2, that causes a new infectious disease COVID-19, emerged at the end of 2019 and conquered the whole world by devastating pandemics that by the middle of May 2020 infected 4.5 million people and caused 350,000 deaths. After originating in China at the end of last December, the virus strongly hit Europe and afterwards the United States of America, which still records the daily growth of 25,000 new cases and makes the USA hardest hit country with 30% of all world cases. The unemployment rates are growing in many affected countries and the International Monetary Fund has declared this pandemic the worst crisis since the depression at the beginning of the 20th century. The pandemic has pushed numerous countries to intervene with strict epidemiologic preventive measures, introducing the infamous lockdown by closing traffic, schools, restaurants, any kind of public gatherings, urging people to stay at home and keep the social distance for weeks. International and national air traffic has been minimalized, millions of people have lost their jobs, the world economy is continuously shrinking with slight chances for rapid recovery. There are still many unknowns about the virus that scientists think first emerged in November 2019. This article reviews the current knowledge about epidemiologic, pathogenetic and clinical patterns of COVID-19, including perspective on therapy, vaccine and future pandemic development.
    Keywords INFEKCIJE KORONAVIRUSOM – dijagnoza ; epidemiologija ; prevencija ; smrtnost ; BETAKORONAVIRUS – genetika ; patogenost ; PROTUVIRUSNI LIJEKOVI – terapijska uporaba ; SINDROM AKUTNOG RESPIRACIJSKOG DISTRESA – dijagnoza ; virologija ; ANGIOTENZIN KONVERTIRAJUĆI ENZIM ; S GLIKOPROTEIN KORONAVIRUSA ; VIRUSNA CJEPIVA ; PANDEMIJA ; CORONAVIRUS INFECTIONS – diagnosis ; epidemiology ; mortality ; prevention and control ; BETACORONAVIRUS – genetics ; pathogenicity; ANTIVIRAL AGENTS – therapeutic use; RESPIRATORY DISTRESS SYNDROME ; ADULT – diagnosis ; virology; PEPTIDYL – DIPEPTIDASE A; SPIKE GLYCOPROTEIN ; CORONAVIRUS; VIRAL VACCINES; PANDEMICS ; covid19
    Language Croatian
    Publisher Croatian medical association
    Publishing country hr
    Document type Article ; Online
    ZDB-ID 128938-x
    ISSN 1849-2177 ; 0024-3477 ; 1330-4917
    ISSN (online) 1849-2177
    ISSN 0024-3477 ; 1330-4917
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  6. Article ; Online: Antiviral treatment significantly reduces the levels of CXCL9, CXCL10 and CXCL11 in chronic hepatitis C.

    Radmanić, Leona / Šimičić, Petra / Bodulić, Kristian / Vince, Adriana / Zidovec-Lepej, Snjezana

    Cytokine

    2024  Volume 176, Page(s) 156529

    Abstract: In this study, we aimed to elucidate the changes in the immune response during antiviral treatment of patients with chronic hepatitis C, with an emphasis on the chemokine dynamics and their association with liver fibrosis. Serum concentrations of 12 ... ...

    Abstract In this study, we aimed to elucidate the changes in the immune response during antiviral treatment of patients with chronic hepatitis C, with an emphasis on the chemokine dynamics and their association with liver fibrosis. Serum concentrations of 12 chemokines. (CCL2, CCL3, CCL4, CCL11, CCL17, CCL20, CXCL1, CXCL5, CXCL8, CXCL9, CXCL10 and CXCL11) were measured in 32 patients with chronic hepatitis C before direct-acting antiviral treatment and after sustained virological response using bead-based flow cytometry. Chemokine levels were also measured in 14 sex- and age-matched healthy individuals. Concentrations of CXCL9, CXCL10, CXCL11 and CCL20 were significantly higher in chronic hepatitis C patients before direct-acting antiviral treatment compared to healthy individuals. We also observed a significant reduction in CXCL9, CXCL10 and CXCL11 levels after sustained virological response. Furthermore, we demonstrated a strong positive correlation between CXCL9, CXCL10 and CXCL11 levels before antiviral treatment. When considering liver fibrosis, we found significantly higher levels of CXCL10 and lower levels of CCL17 and CXCL5 in pre-treatment patients with severe fibrosis. None of the analysed chemokines were able to predict METAVIR fibrosis score reduction after sustained virological response. The results of this study emphasize the importance of proinflammatory pathways in liver fibrosis immunopathology during chronic hepatitis C. Finally, our results also characterized CXCL10 as the chemokine which most accurately distinguished pre-treatment CHC patients and healthy individuals.
    MeSH term(s) Humans ; Hepatitis C, Chronic ; Antiviral Agents/therapeutic use ; Chemokine CXCL10 ; Liver Cirrhosis/drug therapy ; Chemokine CXCL9 ; Chemokine CXCL11
    Chemical Substances Antiviral Agents ; Chemokine CXCL10 ; CXCL9 protein, human ; Chemokine CXCL9 ; CXCL10 protein, human ; CXCL11 protein, human ; Chemokine CXCL11
    Language English
    Publishing date 2024-02-08
    Publishing country England
    Document type Journal Article
    ZDB-ID 1018055-2
    ISSN 1096-0023 ; 1043-4666
    ISSN (online) 1096-0023
    ISSN 1043-4666
    DOI 10.1016/j.cyto.2024.156529
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: TGF Beta as a Prognostic Biomarker of COVID-19 Severity in Patients with NAFLD—A Prospective Case–Control Study

    Frano Susak / Nina Vrsaljko / Adriana Vince / Neven Papic

    Microorganisms, Vol 11, Iss 1571, p

    2023  Volume 1571

    Abstract: Non-alcoholic fatty liver disease (NAFLD), the leading cause of chronic liver disease in Western countries, has been identified as a possible risk factor for COVID-19 severity. However, the immunological mechanisms by which NAFLD exacerbates COVID-19 ... ...

    Abstract Non-alcoholic fatty liver disease (NAFLD), the leading cause of chronic liver disease in Western countries, has been identified as a possible risk factor for COVID-19 severity. However, the immunological mechanisms by which NAFLD exacerbates COVID-19 remain unknown. Transforming growth factor-beta 1 (TGF-β1) has an important immunomodulatory and pro-fibrotic role, which has already been described in NAFLD. However, the role of TGF-β1 in COVID-19 remains unclear, and could also be the pathophysiology link between these two conditions. The aim of this case–control study was to analyze the expression of TGF-β1 in COVID-19 patients depending on the presence of NAFLD and COVID-19 severity. Serum TGF-β1 concentrations were measured in 60 hospitalized COVID-19 patients (30 with NAFLD). NAFLD was associated with higher serum TGF-β1 concentrations that increased with disease severity. Admission TGF-β1 concentrations showed good discriminative accuracy in predicting the development of critical disease and COVID-19 complications (need for advanced respiratory support, ICU admission, time to recovery, development of nosocomial infections and mortality). In conclusion, TGF-β1 could be an efficient biomarker for predicting COVID-19 severity and adverse outcomes in patients with NAFLD.
    Keywords COVID-19 ; SARS-CoV-2 ; non-alcoholic fatty liver disease ; NAFLD ; TGF-β1 ; cytokines ; Biology (General) ; QH301-705.5
    Subject code 610
    Language English
    Publishing date 2023-06-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  8. Article: Nonalcoholic Fatty Liver Disease-A Novel Risk Factor for Recurrent

    Šamadan, Lara / Jeličić, Mia / Vince, Adriana / Papić, Neven

    Antibiotics (Basel, Switzerland)

    2021  Volume 10, Issue 7

    Abstract: ... ...

    Abstract Recurrent
    Language English
    Publishing date 2021-06-27
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2681345-2
    ISSN 2079-6382
    ISSN 2079-6382
    DOI 10.3390/antibiotics10070780
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Unresolved issues in hepatitis C: The role of liver non-parenchymal cells and semaphorins.

    Vince, Adriana / Papic, Neven

    Infectious disease reports

    2018  Volume 10, Issue 1, Page(s) 7232

    Language English
    Publishing date 2018-03-29
    Publishing country Italy
    Document type Journal Article
    ISSN 2036-7430
    ISSN 2036-7430
    DOI 10.4081/idr.2018.7651
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Association of Immune Semaphorins with COVID-19 Severity and Outcomes.

    Vargovic, Martina / Papic, Neven / Samadan, Lara / Balen Topic, Mirjana / Vince, Adriana

    Biomedicines

    2023  Volume 11, Issue 10

    Abstract: Semaphorins have recently been recognized as crucial modulators of immune responses. In the pathogenesis of COVID-19, the activation of immune responses is the key factor in the development of severe disease. This study aimed to determine the association ...

    Abstract Semaphorins have recently been recognized as crucial modulators of immune responses. In the pathogenesis of COVID-19, the activation of immune responses is the key factor in the development of severe disease. This study aimed to determine the association of serum semaphorin concentrations with COVID-19 severity and outcomes. Serum semaphorin concentrations (SEMA3A, -3C, -3F, -4D, -7A) were measured in 80 hospitalized adult patients with COVID-19 (moderate (n = 24), severe (n = 32), critical, (n = 24)) and 40 healthy controls. While SEMA3C, SEMA3F and SEMA7A serum concentrations were significantly higher in patients with COVID-19, SEMA3A was significantly lower. Furthermore, SEMA3A and SEMA3C decreased with COVID-19 severity, while SEMA3F and SEMA7A increased. SEMA4D showed no correlation with disease severity. Serum semaphorin levels show better predictive values than CRP, IL-6 and LDH for differentiating critical from moderate/severe COVID-19. SEMA3F and SEMA7A serum concentrations were associated with the time to recovery, requirement of invasive mechanical ventilation, development of pulmonary thrombosis and nosocomial infections, as well as with in-hospital mortality. In conclusion, we provide the first evidence that SEMA3A, SEMA3C, SEMA3F and SEMA7A can be considered as new biomarkers of COVID-19 severity.
    Language English
    Publishing date 2023-10-13
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2720867-9
    ISSN 2227-9059
    ISSN 2227-9059
    DOI 10.3390/biomedicines11102786
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top